ΠΠΌΠΌΡΠ½ΠΎΡΠ΅Π½ΠΎΡΠΈΠΏ ΠΈ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½Π°Ρ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ², Π²ΡΠ΄Π΅Π»Π΅Π½Π½ΡΡ ΠΈΠ· ΠΏΠ΅ΡΠ΅Π½ΠΈ, ΠΏΠΎΡΠ°ΠΆΠ΅Π½Π½ΠΎΠΉ ΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΡΠΌ ΠΏΡΠΎΡΠ΅ΡΡΠΎΠΌ
![ΠΠΈΡΡΠ΅ΡΡΠ°ΡΠΈΡ: ΠΠΌΠΌΡΠ½ΠΎΡΠ΅Π½ΠΎΡΠΈΠΏ ΠΈ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½Π°Ρ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ², Π²ΡΠ΄Π΅Π»Π΅Π½Π½ΡΡ
ΠΈΠ· ΠΏΠ΅ΡΠ΅Π½ΠΈ, ΠΏΠΎΡΠ°ΠΆΠ΅Π½Π½ΠΎΠΉ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΠΌ ΠΏΡΠΎΡΠ΅ΡΡΠΎΠΌ](https://gugn.ru/work/2739088/cover.png)
Π ΠΏΠ°ΡΠ΅Π½Ρ ΠΈΠΌΠ΅ ΠΏΠ΅ΡΠ΅Π½ΠΈ ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΡΡ ΠΆΠΈΠ²ΠΎΡΠ½ΡΡ Ρ ΠΈΠΌΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΎΠΏΡΡ ΠΎΠ»ΡΡ ΠΈ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·Π°ΠΌΠΈ ΠΎΡΠΌΠ΅ΡΠ°Π΅ΡΡΡ Π»ΠΈΠΌΡΠΎΠΈΠ΄Π½Π°Ρ ΠΈΠ½ΡΠΈΠ»ΡΡΡΠ°ΡΠΈΡ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π²ΡΡΠ°ΠΆΠ΅Π½Π½Π°Ρ Π² ΠΏΠ°ΡΠ°ΡΡΠΌΠΎΡΠ°Π»ΡΠ½ΡΡ ΡΡΠ°ΡΡΠΊΠ°Ρ .2. ΠΠΎ ΡΠ²ΠΎΠΈΠΌ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΠ²ΠΎΠΉΡΡΠ²Π°ΠΌ ΠΏΠ΅ΡΠ΅Π½Ρ-Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ Π»ΠΈΠΌΡΠΎΡΠΈΡΡ ΠΌΠΎΠ³ΡΡ Π±ΡΡΡ ΠΎΡΠ½Π΅ΡΠ΅Π½Ρ ΠΊ Π°ΠΊΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌ ΡΠΎΡΠΌΠ°ΠΌ ΡΠΈΠΏΠ° ΠΈΠΌΠΌΡΠ½ΠΎΠ±Π»Π°ΡΡΠΎΠ² ΠΈ ΠΏΡΠΎΠ»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ².3. ΠΠ½ΡΠΈΠ»ΡΡΡΠΈΡΡΡΡΠΈΠ΅ ΠΏΠΎΡΠ°ΠΆΠ΅Π½Π½ΡΡ ΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΡΠΌ ΠΏΡΠΎΡΠ΅ΡΡΠΎΠΌ… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
- Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- ΠΡΠ΄Π΅ΡΠΆΠΊΠ°
- ΠΠΈΡΠ΅ΡΠ°ΡΡΡΠ°
- ΠΡΡΠ³ΠΈΠ΅ ΡΠ°Π±ΠΎΡΡ
- ΠΠΎΠΌΠΎΡΡ Π² Π½Π°ΠΏΠΈΡΠ°Π½ΠΈΠΈ
Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- 1. ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅
- 2. ΠΠ±Π·ΠΎΡ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- 3. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ
- 4. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ
- 4. 1. ΠΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ° ΠΌΠΎΠ½ΠΎΠ½ΡΠΊΠ»Π΅Π°ΡΠ½ΡΡ Π»Π΅ΠΉΠΊΠΎΡΠΈΡΠΎΠ², ΠΈΠ½ΡΠΈΠ»ΡΡΡΠΈΡΡΡΡΠΈΡ ΠΎΠΏΡΡ ΠΎΠ»ΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΈ Ρ ΠΌΡΡΠ΅ΠΉ
- 4. 2. ΠΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅Π½ΠΎΡΠΈΠΏΠ° ΠΌΠΎΠ½ΠΎΠ½ΡΠΊΠ»Π΅Π°ΡΠ½ΡΡ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² ΠΏΠ΅ΡΠ΅Π½ΠΈ ΠΌΡΡΠ΅ΠΉ, ΠΏΠΎΡΠ°ΠΆΠ΅Π½Π½ΠΎΠΉ ΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΡΠΌ ΠΏΡΠΎΡΠ΅ΡΡΠΎΠΌ
- 4. 3. Π¦ΠΈΡΠΎΡΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ², Π²ΡΠ΄Π΅Π»Π΅Π½Π½ΡΡ ΠΈΠ· ΠΏΠ΅ΡΠ΅Π½ΠΈ
- 4. 4. ΠΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΠΈΠ½ΡΠΈΠ»ΡΡΡΠ°ΡΠΈΠΈ ΠΌΠΎΠ½ΠΎΠ½ΡΠΊΠ»Π΅Π°ΡΠ½ΡΠΌΠΈ Π»Π΅ΠΉΠΊΠΎΡΠΈΡΠ°ΠΌΠΈ ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠ·Π»ΠΎΠ² ΠΏΠ΅ΡΠ΅Π½ΠΈ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ
- 4. 5. ΠΠΈΠ»Π»Π΅ΡΠ½Π°Ρ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ², Π²ΡΠ΄Π΅Π»Π΅Π½Π½ΡΡ ΠΈΠ· ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΠ°ΡΡΠ°ΠΈΡΠ΅ΡΠΊΠΈΡ ΠΈ ΠΈΠ½ΡΠ°ΠΊΡΠ½ΡΡ ΡΡΠ°ΡΡΠΊΠΎΠ² ΠΏΠ΅ΡΠ΅Π½ΠΈ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ
- 4. 6. ΠΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΠΈΠΌΡΠ½ΠΎΡΠ΅Π½ΠΎΡΠΈΠΏΠ° ΠΌΠΎΠ½ΡΠΊΠ»Π΅Π°ΡΠ½ΡΡ Π»Π΅ΠΉΠΊΠΎΡΠΈΡΠΎΠ² ΠΏΠ΅ΡΠ΅Π½ΠΈ
- 4. 7. ΠΠ΅Π½Π΅ΡΠ°ΡΠΈΡ ΠΠΠ ΠΈΠ· Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ², Π²ΡΠ΄Π΅Π»Π΅Π½Π½ΡΡ ΠΈΠ· ΠΏΠ΅ΡΠ΅Π½ΠΈ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ
- 5. ΠΠ±ΡΡΠΆΠ΄Π΅Π½ΠΈΠ΅
- ΠΡΠ²ΠΎΠ΄Ρ
ΠΠΌΠΌΡΠ½ΠΎΡΠ΅Π½ΠΎΡΠΈΠΏ ΠΈ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½Π°Ρ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ², Π²ΡΠ΄Π΅Π»Π΅Π½Π½ΡΡ ΠΈΠ· ΠΏΠ΅ΡΠ΅Π½ΠΈ, ΠΏΠΎΡΠ°ΠΆΠ΅Π½Π½ΠΎΠΉ ΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΡΠΌ ΠΏΡΠΎΡΠ΅ΡΡΠΎΠΌ (ΡΠ΅ΡΠ΅ΡΠ°Ρ, ΠΊΡΡΡΠΎΠ²Π°Ρ, Π΄ΠΈΠΏΠ»ΠΎΠΌ, ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½Π°Ρ)
ΠΠΊΡΡΠ°Π»ΡΠ½ΠΎΡΡΡ ΡΠ΅ΠΌΡ
ΠΠ°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΡ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠΌΠΈ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ Π² ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΠ΅ Π΄Π΅ΡΡΡΠΈΠ»Π΅ΡΠΈΡ Π² Π ΠΎΡΡΠΈΠΈ ΠΏΠΎΡΡΠΎΡΠ½Π½ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ°Π΅Ρ ΠΈ, ΠΊΠ°ΠΊ ΠΏΠΎΠΊΠ°Π·ΡΠ²Π°ΡΡ ΡΠ°ΡΡΠ΅ΡΡ, ΠΏΡΠΈΡΠΎΡΡ ΡΠΈΡΠ»Π° ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ Π² XXI Π²Π΅ΠΊΠ΅ Π±ΡΠ΄Π΅Ρ ΠΏΠΎΡΡΠΎΡΠ½Π½ΠΎ ΡΠ²Π΅Π»ΠΈΡΠΈΠ²Π°ΡΡΡΡ. ΠΠ° ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΌ ΡΡΠ°ΠΏΠ΅, Π½Π΅ΡΠΌΠΎΡΡΡ Π½Π° ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½Ρ, ΠΏΠΎ-ΠΏΡΠ΅ΠΆΠ½Π΅ΠΌΡ ΠΎΡΠ½ΠΎΠ²Π½ΡΠΌΠΈ ΠΌΠ΅ΡΠΎΠ΄Π°ΠΌΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ ΡΠ°ΠΊΠ° ΠΎΡΡΠ°Π΅ΡΡΡ Ρ ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΈ Ρ ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ. ΠΡΠΈ ΠΎΡΠ½ΠΎΠ²Π½ΡΡ Π»ΠΎΠΊΠ°Π»ΠΈΠ·Π°ΡΠΈΡΡ Π½Π΅ΠΎΠΏΠ»Π°Π·ΠΈΠΉ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Ρ ΡΠ΅Π·Π΅ΠΊΡΠ°Π±Π΅Π»ΡΠ½ΠΎΡΡΠΈ ΠΏΠΎ ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΡ ΠΊ ΡΠΈΡΠ»Ρ Π·Π°Π±ΠΎΠ»Π΅Π²ΡΠΈΡ Π½Π΅ ΠΏΡΠ΅Π²ΡΡΠ°Π΅Ρ 20 Π° ΠΎΠΊΠΎΠ»ΠΎ 50 ΠΎΠΏΠ΅ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ Π±ΠΎΠ»ΡΠ½ΡΡ ΡΠΌΠΈΡΠ°ΡΡ Π² ΠΏΠ΅ΡΠ²ΡΠ΅ Π΄Π²Π° Π³ΠΎΠ΄Π° ΠΎΡ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ. ΠΠΎΡΠ»Π΅ ΡΠ°Π΄ΠΈΠΊΠ°Π»ΡΠ½ΡΡ ΠΈ ΡΡΠ»ΠΎΠ²Π½ΠΎ-ΡΠ°Π΄ΠΈΠΊΠ°Π»ΡΠ½ΡΡ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΉ Π±ΠΎΠ»ΡΠ½ΡΠ΅ ΡΠΌΠΈΡΠ°ΡΡ Π½Π΅ ΡΡΠΎΠ»ΡΠΊΠΎ ΠΎΡ ΡΠ΅ΡΠΈΠ΄ΠΈΠ²Π° ΠΎΠΏΡΡ ΠΎΠ»ΠΈ, ΡΠΊΠΎΠ»ΡΠΊΠΎ ΠΎΡ ΠΎΡΠ΄Π°Π»Π΅Π½Π½ΡΡ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΎΠ², ΡΡΠΎ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΠ΅Ρ ΠΎ Π½Π΅ΠΎΠ±Ρ ΠΎΠ΄ΠΈΠΌΠΎΡΡΠΈ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ Π΄Π°ΠΆΠ΅ ΠΏΡΠΈ ΠΌΠ΅ΡΡΠ½ΠΎΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΡΡ ΡΠΎΡΠΌΠ°Ρ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ. Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΡΡ Π΅ΠΌΡ Ρ ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΎΠΊΠ°Π·ΡΠ²Π°ΡΡΡΡ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΠΌΠΈ, ΠΏΡΠ΅ΠΆΠ΄Π΅ Π²ΡΠ΅Π³ΠΎ, ΠΏΡΠΈ ΡΠ°ΠΊ Π½Π°Π·ΡΠ²Π°Π΅ΠΌΡΡ ΠΈΠΌΠΌΡΠ½ΠΎΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΡΡ ΡΠΎΡΠΌΠ°Ρ Π½Π΅ΠΎΠΏΠ»Π°Π·ΠΈΠΉ (ΠΌΠ΅Π»Π°Π½ΠΎΠΌΠ°, ΡΠ°ΠΊ ΠΏΠΎΡΠΊΠΈ) ΠΈ ΡΡΠ΄Π΅ ΠΎΡΠ½ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΠΎ Ρ ΠΈΠΌΠΈΠΎΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΡΡ ΡΠΎΡΠΌ ΡΠ°ΠΊΠ° (Π½Π΅ΠΌΠ΅Π»ΠΊΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΉ ΡΠ°ΠΊ Π»Π΅Π³ΠΊΠΎΠ³ΠΎ, ΡΠ°ΠΊ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ°, ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ ΠΏΠ΅ΡΠ΅Π½ΠΈ ΠΈ Ρ. ΠΏ.). ΠΠΎΡΡΠΎΠΌΡ ΠΏΠΎΠΈΡΠΊ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ², Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½Π½ΡΡ Π½Π° ΡΡΠΈΠΌΡΠ»ΡΡΠΈΡ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΠΈΠΌΠΌΡΠ½ΠΈΡΠ΅ΡΠ° ΠΈ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ ΡΠ°ΡΠΏΠΎΠ·Π½Π°Π²Π°Π΅ΠΌΠΎΡΡΠΈ ΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΡΡ Π°Π½ΡΠΈΠ³Π΅Π½ΠΎΠ², ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΠ΅ΡΡΡ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΠΌ [ΠΠ°Π²ΡΠ΄ΠΎΠ² Π. Π. Ρ ΡΠΎΠ°Π²Ρ., 2000]. ΠΠΏΡΡ ΠΎΠ»Π΅Π²ΠΎΠ΅ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠ΅ ΠΏΠ΅ΡΠ΅Π½ΠΈ ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ ΠΊΠ°ΠΊ ΡΠ°ΠΌΠΎΡΡΠΎΡΡΠ΅Π»ΡΠ½ΡΠΌ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅ΠΌ, ΡΠ°ΠΊ ΠΈ ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ, ΠΈ ΠΎΡΠΌΠ΅ΡΠ°Π΅ΡΡΡ ΠΏΡΠΈ ΠΌΠ½ΠΎΠ³ΠΈΡ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΡ . ΠΠΎ ΠΈ Π² ΡΠΎΠΌ ΠΈ Π² Π΄ΡΡΠ³ΠΎΠΌ ΡΠ»ΡΡΠ°Π΅ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ ΠΊΠ°ΠΊ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠ³ΠΎ, ΡΠ°ΠΊ ΠΈ ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ·Π»Π° Π² ΠΏΠ΅ΡΠ΅Π½ΠΈ ΡΠΊΠ°Π·ΡΠ²Π°Π΅Ρ Π½Π° ΡΠ΅Π·ΠΊΠΎΠ΅ ΡΡ ΡΠ΄ΡΠ΅Π½ΠΈΠ΅ ΠΏΡΠΎΠ³Π½ΠΎΠ·Π° Π² ΡΠ΅ΡΠ΅Π½ΠΈΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ. Π’Π°ΠΊΠΎΠ΅ ΡΡ ΡΠ΄ΡΠ΅Π½ΠΈΠ΅ ΠΏΡΠΎΠ³Π½ΠΎΠ·Π° ΡΠ²ΡΠ·ΡΠ²Π°ΡΡ Ρ ΡΠ΅ΠΌ, ΡΡΠΎ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠ° Π² ΠΏΠ΅ΡΠ΅Π½ΠΈ ΠΌΠΎΠΆΠ΅Ρ Π½Π°Π±Π»ΡΠ΄Π°ΡΡΡΡ Π½Π° ΡΠΎΠ½Π΅ ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈ ΠΏΠΎΠ»Π½ΠΎΠ³ΠΎ ΠΈΡΡΠΎΡΠ΅Π½ΠΈΡ ΠΈΠΌΠΌΡΠ½Π½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ ΠΎΡΠ³Π°Π½ΠΈΠ·ΠΌΠ° ΠΈ, Π² ΡΠ°ΡΡΠ½ΠΎΡΡΠΈ, ΠΈΠΌΠΌΡΠ½Π½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ ΡΡΠΎΠ³ΠΎ ΠΎΡΠ³Π°Π½Π°. ΠΠΌΠΌΡΠ½Π½Π°Ρ ΡΠΈΡΡΠ΅ΠΌΠ° ΠΏΠ΅ΡΠ΅Π½ΠΈΠ²ΠΊΠ»ΡΡΠ°Π΅Ρ Π² ΡΠ΅Π±Ρ* Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²ΠΎ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠΎΠ² Π²ΡΠΎΠΆΠ΄Π΅Π½Π½ΠΎΠΉ ΠΈΠΌΠΌΡΠ½Π½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ: Π½Π°ΡΡΡΠ°Π»ΡΠ½ΡΠ΅ ΠΊΠΈΠ»Π»Π΅ΡΡ (ΠΠ), Π½Π°ΡΡΡΠ°Π»ΡΠ½ΡΠ΅ ΠΊΠΈΠ»Π»Π΅ΡΡ-Π’-ΠΊΠ»Π΅ΡΠΊΠΈ (ΠΠΠ’-ΠΊΠ»Π΅ΡΠΊΠΈ), Π΄Π΅Π½Π΄ΡΠΈΡΠ½ΡΠ΅ ΠΊΠ»Π΅ΡΠΊΠΈ, ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΈ ΠΈ Π΄Ρ: ΠΈ Π½Π΅Π±ΠΎΠ»ΡΡΡΡ ΡΠ°ΡΡΡ ΡΡΡΠ΅ΠΊΡΠΎΡΠΎΠ²ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ* ΠΈΠΌΠΌΡΠ½ΠΈΡΠ΅ΡΠ° (Π’-ΠΊΠ»Π΅ΡΠΊΠΈ) [Beaudoih L. et al., 2002] i ΠΠ·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·Ρ ΠΌΠ΅ΠΆΠ΄Ρ ΡΡΠΈΠΌΠΈ Π΄Π²ΡΠΌΡ Π·Π²Π΅Π½ΡΡΠΌΠΈ ΠΈΠΌΠΌΡΠ½Π½ΠΎΠΉ Π·Π°ΡΠΈΡΡ ΠΏΠ΅ΡΠ΅Π½ΠΈ Π΄ΠΎΠΊΠΎΠ½ΡΠ° Π½Π΅ ΠΈΠ·ΡΡΠ΅Π½Π°. Π-ΡΠΎΠ»ΠΈ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈΠΌΠΌΡΠ½Π½ΠΎΠ³ΠΎ ΠΎΡΠ²Π΅ΡΠ° ΠΈΠ·Π²Π΅ΡΡΠ½ΠΎ Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ ΠΌΠ½ΠΎΠ³ΠΎΠ³ΠΎΡΠ°Π·Π΄ΠΎ ΠΌΠ΅Π½ΡΡΠ΅ ΡΠ²Π΅Π΄Π΅Π½ΠΈΠΉ, ΠΏΠΎΡΠ²ΡΡΠ΅Π½ΠΎ, Π΄ΡΡΠ³ΠΈΠΌ ΡΡΠ±ΠΊΠ»Π°ΡΡΠ°ΠΌ ΠΌΠΎΠ½ΠΎΠ½ΡΠΊΠ»Π΅Π°ΡΠ½ΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΏΠ΅ΡΠ΅Π½ΠΈ-, ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎ ΠΎΠ±ΠΈΡ ΡΡΠ°ΡΡΠΈΠΈΠ² ΠΈΠ½ΠΈΡΠΈΠ°ΡΠΈΠΈ ΠΈΠΌΠΌΡΠ½Π½ΠΎΠ³ΠΎ ΠΎΡΠ²Π΅ΡΠ°. ΠΠΠ’-ΠΊΠ»Π΅ΡΠΊΡ ΠΏΠ΅ΡΠ΅Π½ΠΈ ΡΠΎΡΡΠ°Π²Π»ΡΡΡ ΠΎΡΠ½ΠΎΠ²Π½ΡΡ ΡΠ°ΡΡΡ Π’-ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΉ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΈ ΡΡΠΎΠ³ΠΎ ΠΎΡΠ³Π°Π½Π°: ΠΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡ ΠΎ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΈ*ΠΠΠ’-ΠΊΠ»Π΅ΡΠΎΠΊ Π²* ΠΏΠ΅ΡΠ΅Π½ΠΈ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° Π²Π΅ΡΡΠΌΠ° ΠΌΠ°Π»ΠΎΡΠΈΡΠ»Π΅Π½Π½Π° ΠΈ ΠΏΡΠΎΡΠΈΠ²ΠΎΡΠ΅ΡΠΈΠ²Π°ΠΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈ Π²ΡΠ΅ ΡΠ²Π΅Π΄Π΅Π½ΠΈΡ ΠΎΠ± ΠΈΡ Π²Π½ΡΡΡΠΈΠΏΠ΅ΡΡΠ½ΠΎΡΠ½ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ ΠΈ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠΈ Ρ Π΄ΡΡΠ³ΠΈΠΌΠΈ Π·Π²Π΅Π½ΡΡΠΌΠΈ ΠΈΠΌΠΌΡΠ½Π½ΠΎΡ ΡΠΈΡΡΠ΅ΠΌΡ, ΠΏΠ΅ΡΠ΅Π½ΠΈ-Π±ΡΠ»ΠΈ ΠΏΠΎΠ»ΡΡΠ΅Π½Ρ Π² ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ΅ Π½Π° ΠΌΡΡΠ°Ρ . ΠΠ΄Π½Π°ΠΊΠΎ ΡΡΠ°ΡΡΠΈΠ΅ ΠΠΠ’-ΠΊΠ»Π΅ΡΠΎΠΊ ΠΏΠ΅ΡΠ΅Π½ΠΈ Π² ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΠΎΠΌ ΠΈΠΌΠΌΡΠ½ΠΈΡΠ΅ΡΠ΅ ΠΎΡΡΠ°Π΅ΡΡΡ ΠΌΠ°Π»ΠΎ ΠΈΠ·ΡΡΠ΅Π½Π½ΡΠΌ [Berzins S. P: et-ali, 2004]i ΠΡΠ΅Π²ΠΈΠ΄Π½ΡΠΌ ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΡΠΎ ΠΠΠ’-ΠΊΠ»Π΅ΡΠΊΠΈ ΠΎΡ Π²Π°ΡΡΠ²Π°ΡΡ Π±ΠΎΠ»Π΅Π΅ Π³Π΅ΡΠ΅ΡΠΎΠ³Π΅Π½Π½ΡΡ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΡ Π’-Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ², ΡΠ΅ΠΌ ΡΡΠΈΡΠ°Π»ΠΎΡΡ ΠΈΠ·Π½Π°ΡΠ°Π»ΡΠ½ΠΎ- [Fuji N. et al., 2000]. ΠΠ°Π»ΡΠ½Π΅ΠΉΡΠΈΠΉ Π°Π½Π°Π»ΠΈΠ· ΡΡΠ½ΠΊΡΠΈΠΉ ΠΠΠ’-ΠΊΠ»Π΅ΡΠΎΠΊ ΠΏΠ΅ΡΠ΅Π½ΠΈ ΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΈΡ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅Π½ΠΎΡΠΈΠΏΠ°, ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΊΡΠ°ΠΉΠ½Π΅ Π²Π°ΠΆΠ½ΡΠΌ Π² ΠΎΡΠ΅Π½ΠΊΠ΅ ΡΠΎΠ»ΠΈ ΠΠΠ’-ΠΊΠ»Π΅ΡΠΎΠΊ Π² ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΠΎΠΌ ΠΈΠΌΠΌΡΠ½ΠΈΡΠ΅ΡΠ΅. Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅Π½ΠΎΡΠΈΠΏΠ° ΠΈ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΌΠΎΠ½ΠΎΠ½ΡΠΊΠ»Π΅Π°ΡΠ½ΡΡ Π»Π΅ΠΉΠΊΠΎΡΠΈΡΠΎΠ², Π²ΡΠ΄Π΅Π»Π΅Π½Π½ΡΡ ΠΈΠ· ΠΏΠ΅ΡΠ΅Π½ΠΈ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ , ΠΏΠΎΡΠ°ΠΆΠ΅Π½Π½ΠΎΠΉ ΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΡΠΌΠ΅ΠΏΡΠΎΡΠ΅ΡΡΠΎΠΌ. ΠΠ°Π΄Π°ΡΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ 1. ΠΠ·ΡΡΠΈΡΡ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² Π² ΠΏΠΎΡΠ°ΠΆΠ΅Π½Π½ΡΡ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·Π°ΠΌΠΈ, ΠΈ ΠΈΠ½ΡΠ°ΠΊΡΠ½ΡΡ ΡΡΠ°ΡΡΠΊΠ°Ρ ΠΏΠ΅ΡΠ΅Π½ΠΈ. 2. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΡ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² ΠΏΠ΅ΡΠ΅Π½ΠΈ, ΠΏΠΎΡΠ°ΠΆΠ΅Π½Π½ΠΎΠΉ ΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΡΠΌ ΠΏΡΠΎΡΠ΅ΡΡΠΎΠΌ. 3. ΠΡΠ΅Π½ΠΈΡΡ ΡΠΈΡΠΎΡΠΎΠΊΡΠΈΡΠ΅ΡΠΊΡΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² ΠΈΠ· ΠΏΠ°ΡΠ°ΡΡΠΌΠΎΡΠ°Π»ΡΠ½ΠΎΠΉ> ΠΎΠ±Π»Π°ΡΡΠΈ ΠΈ ΠΏΠ΅ΡΠΈΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΡΠΎΠ²ΠΈ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ . 4. ΠΡΠΎΠ²Π΅ΡΡΠΈ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅Π½ΠΎΡΠΈΠΏΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΌΠΎΠ½ΠΎΠ½ΡΠΊΠ»Π΅Π°ΡΠ½ΡΡ Π»Π΅ΠΉΠΊΠΎΡΠΈΡΠΎΠ² ΠΏΠ°ΡΠ°ΡΡΠΌΠΎΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΎΠ±Π»Π°ΡΡΠΈ ΠΈ ΠΈΠ½ΡΠ°ΠΊΡΠ½ΡΡ ΡΡΠ°ΡΡΠΊΠΎΠ² ΠΏΠ΅ΡΠ΅Π½ΠΈ. 5. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΡ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅Π½ΠΎΡΠΈΠΏΠ°ΠΈ ΠΊΠΈΠ»Π»Π΅ΡΠ½ΡΡ ΡΠ²ΠΎΠΉΡΡΠ² Π»ΠΈΠΌΡΠΎΠΊΠΈΠ½Π°ΠΊΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ ΠΊΠΈΠ»Π»Π΅ΡΠΎΠ², Π³Π΅Π½Π΅ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ ΠΈΠ· ΠΌΠΎΠ½ΠΎΠ½ΡΠΊΠ»Π΅Π°ΡΠ½ΡΡ Π»Π΅ΠΉΠΊΠΎΡΠΈΡΠΎΠ² ΠΏΠ°ΡΠ°ΡΡΠΌΠΎΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΎΠ±Π»Π°ΡΡΠΈ, ΠΈΠ½ΡΠ°ΠΊΡΠ½ΠΎΠ³ΠΎ ΡΡΠ°ΡΡΠΊΠ° ΠΏΠ΅ΡΠ΅Π½ΠΈ ΠΈ ΠΏΠ΅ΡΠΈΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΡΠΎΠ²ΠΈ. ΠΠ°ΡΡΠ½Π°Ρ Π½ΠΎΠ²ΠΈΠ·Π½Π° ΠΠΏΠ΅ΡΠ²ΡΠ΅ Π² ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΌ Π°ΡΠΏΠ΅ΠΊΡΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅Π½ΠΎΡΠΈΠΏΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠ΅ ΡΠ²ΠΎΠΉΡΡΠ²Π° Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ², Π²ΡΠ΄Π΅Π»Π΅Π½Π½ΡΡ ΠΈΠ· ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ, ΠΈΠ½ΡΠ°ΠΊΡΠ½ΠΎΠ³ΠΎ ΡΡΠ°ΡΡΠΊΠΎΠ² ΠΏΠ΅ΡΠ΅Π½ΠΈ ΠΈ ΠΏΠ΅ΡΠΈΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΡΠΎΠ²ΠΈ, ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ . Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΡΡ ΠΈΠΌΠΌΡΠ½Π½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠ° ΠΏΡΠΈ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΡ ΠΏΠ΅ΡΠ΅Π½ΠΈ ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ Π»ΠΈΠΌΡΠΎΠΈΠ΄Π½ΡΡ ΠΈΠ½ΡΠΈΠ»ΡΡΡΠ°ΡΠΎΠ² Π² ΠΏΠ°ΡΠ°ΡΡΠΌΠΎΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΎΠ±Π»Π°ΡΡΠΈ. ΠΠΏΠ΅ΡΠ²ΡΠ΅ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ Π»ΠΈΠΌΡΠΎΡΠΈΡΡ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΠ±Π»Π°ΡΡΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΈ ΠΎΠ±Π»Π°Π΄Π°ΡΡ Π²ΡΡΠΎΠΊΠΎΠΉ ΡΠΏΠΎΠ½ΡΠ°Π½Π½ΠΎΠΉ ΡΠΈΡΠΎΡΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΈ ΠΠ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΡ, ΡΠΎΠΏΠΎΡΡΠ°Π²ΠΈΠΌΠΎΠΉ Ρ ΡΠ°ΠΊΠΎΠ²ΠΎΠΉ Π΄Π»Ρ ΠΠΠ. ΠΠΏΠ΅ΡΠ²ΡΠ΅ ΠΏΠΎΠΊΠ°Π·Π°Π½Π° Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΡ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΈΡ ΠΈΠ· Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² ΠΏΠ΅ΡΠ΅Π½ΠΈ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ ΠΠΠ, ΡΠΏΠΎΡΠΎΠ±Π½ΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎ Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°ΡΡ Π°ΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ½ΡΠ΅ ΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΡΠ΅ ΠΊΠ»Π΅ΡΠΊΠΈ. ΠΠΏΠ΅ΡΠ²ΡΠ΅ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ Π² ΠΎΠ±Π»Π°ΡΡΠΈ ΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΡΡ ΡΠ·Π»ΠΎΠ² ΠΎΠ±ΡΠ°Π·ΡΡΡΡΡΠ»ΠΈΠΌΡΠΎΠΈΠ΄Π½ΡΠ΅ ΠΈΠ½ΡΠΈΠ»ΡΡΡΠ°ΡΡ, ΡΠΎΡΡΠΎΡΡΠΈΠ΅ ΠΈΠ· Π’-Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ², ΠΠ ΠΈ ΠΠΠ’, Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΡΡΠΈΡ ΡΡ Π²ΡΡΠΎΠΊΠΈΠΌ ΡΡΠΎΠ²Π½Π΅ΠΌ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΎΠ»Π΅ΠΊΡΠ» Π°Π΄Π³Π΅Π·ΠΈΠΈ ΠΈ ΠΌΠ°ΡΠΊΠ΅ΡΠ° ΠΏΡΠΎΠ»ΠΈΡΠ΅ΡΠ°ΡΠΈΠΈ Ki-67. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅Π½ΠΎΡΠΈΠΏΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠ΅ ΡΠ²ΠΎΠΉΡΡΠ²Π° ΠΠΠ, Π³Π΅Π½Π΅ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ ΠΈΠ· Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ², ΠΈΠ½ΡΠΈΠ»ΡΡΡΠΈΡΡΡΡΠΈΡ ΠΏΠ΅ΡΠ΅Π½Ρ. ΠΠΎΠ»ΡΡΠ΅Π½Ρ Π½ΠΎΠ²ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΠΎ ΡΠΎΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ ΡΡΠ±ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΈ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² Π² ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ ΡΡΠ°ΡΡΠΊΠ°Ρ ΠΏΠ΅ΡΠ΅Π½ΠΈ Π½Π° ΡΠΎΠ½Π΅ ΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΠΎΠΉ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΠΈ. ΠΠ°ΡΡΠ½ΠΎ-ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡ ΠΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ Π² ΡΠ°Π±ΠΎΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΡΠ°ΡΡΠΈΡΡΡΡ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ΠΈΡ ΠΎ ΠΌΠ΅Ρ Π°Π½ΠΈΠ·ΠΌΠ°Ρ ΠΌΠ΅ΡΡΠ½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΠΈΠΌΠΌΡΠ½ΠΈΡΠ΅ΡΠ°. Π Ρ ΠΎΠ΄Π΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΎΡΡΠ°Π±ΠΎΡΠ°Π½ Π°Π»Π³ΠΎΡΠΈΡΠΌ ΡΠΊΡΡΡΠ°ΠΊΠΎΡΠΏΠΎΡΠ°Π»ΡΠ½ΠΎΠΉ Π³Π΅Π½Π΅ΡΠ°ΡΠΈΠΈ ΠΈΠ· Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ², Π²ΡΠ΄Π΅Π»Π΅Π½Π½ΡΡ ΠΈΠ· ΠΏΠΎΡΠ°ΠΆΠ΅Π½Π½ΠΎΠΉ ΠΊΠΈΠ»Π»Π΅ΡΠ½ΠΎΠΉ ΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΡΠΌ ΠΏΡΠΎΡΠ΅ΡΡΠΎΠΌ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΈ, ΠΠΠ Ρ Π²ΡΡΠΎΠΊΠΈΠΌ ΠΊ Π°ΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ½ΡΠΌ ΡΡΠΎΠ²Π½Π΅ΠΌ ΠΏΠΎ ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΡ ΠΊΠ»Π΅ΡΠΊΠ°ΠΌ. ΠΠΠ, Π³Π΅Π½Π΅ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ ΠΈΠ· Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² ΠΏΠ΅ΡΠ΅Π½ΠΈ, ΠΌΠΎΠ³ΡΡ Π±ΡΡΡ Π»ΠΎΠΊΠΎΡΠ΅Π³ΠΈΠΎΠ½Π°ΡΠ½ΠΎΠΉ ΡΠ°Π΄ΠΈΠΊΠ°Π»ΡΠ½ΠΎ Π°Π΄ΠΎΠΏΡΠΈΠ²Π½ΠΎΠΉ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ Ρ ΡΠ΅Π»ΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½Ρ Π΄Π»Ρ ΠΈ ΡΡΠ»ΠΎΠ²Π½ΠΎΡΠ΅ΡΠΈΠ΄ΠΈΠ²ΠΎΠ² ΡΠ°Π΄ΠΈΠΊΠ°Π»ΡΠ½ΠΎ ΠΎΠΏΠ΅ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ Π±ΠΎΠ»ΡΠ½ΡΡ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π² ΠΏΠ΅ΡΠ΅Π½ΠΈ.
1. Π ΠΏΠ°ΡΠ΅Π½Ρ ΠΈΠΌΠ΅ ΠΏΠ΅ΡΠ΅Π½ΠΈ ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΡΡ ΠΆΠΈΠ²ΠΎΡΠ½ΡΡ Ρ ΠΈΠΌΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΎΠΏΡΡ ΠΎΠ»ΡΡ ΠΈ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·Π°ΠΌΠΈ ΠΎΡΠΌΠ΅ΡΠ°Π΅ΡΡΡ Π»ΠΈΠΌΡΠΎΠΈΠ΄Π½Π°Ρ ΠΈΠ½ΡΠΈΠ»ΡΡΡΠ°ΡΠΈΡ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π²ΡΡΠ°ΠΆΠ΅Π½Π½Π°Ρ Π² ΠΏΠ°ΡΠ°ΡΡΠΌΠΎΡΠ°Π»ΡΠ½ΡΡ ΡΡΠ°ΡΡΠΊΠ°Ρ .2. ΠΠΎ ΡΠ²ΠΎΠΈΠΌ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΠ²ΠΎΠΉΡΡΠ²Π°ΠΌ ΠΏΠ΅ΡΠ΅Π½Ρ-Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ Π»ΠΈΠΌΡΠΎΡΠΈΡΡ ΠΌΠΎΠ³ΡΡ Π±ΡΡΡ ΠΎΡΠ½Π΅ΡΠ΅Π½Ρ ΠΊ Π°ΠΊΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌ ΡΠΎΡΠΌΠ°ΠΌ ΡΠΈΠΏΠ° ΠΈΠΌΠΌΡΠ½ΠΎΠ±Π»Π°ΡΡΠΎΠ² ΠΈ ΠΏΡΠΎΠ»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ².3. ΠΠ½ΡΠΈΠ»ΡΡΡΠΈΡΡΡΡΠΈΠ΅ ΠΏΠΎΡΠ°ΠΆΠ΅Π½Π½ΡΡ ΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΡΠΌ ΠΏΡΠΎΡΠ΅ΡΡΠΎΠΌ ΠΏΠ΅ΡΠ΅Π½Ρ Π»ΠΈΠΌΡΠΎΡΠΈΡΡ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ ΡΡΠ΅ΠΌΡ ΠΎΡΠ½ΠΎΠ²Π½ΡΠΌΠΈ ΡΡΠ±ΠΏΠΎΠΏΡΠ»ΡΡΠΈΡΠΌΠΈ: Π’-ΠΊΠ»Π΅ΡΠΊΠ°ΠΌΠΈ (CD3*), ΠΠ (CD16+, CD56+, CD574) ΠΈ ΠΠΠ’ (CD3+/CD56+).4. ΠΠΎΠ½ΠΎΠ½ΡΠΊΠ»Π΅Π°ΡΠ½ΡΠ΅ Π»Π΅ΠΉΠΊΠΎΡΠΈΡΡ ΠΏΠ΅ΡΠ΅Π½ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ , Π²ΡΠ΄Π΅Π»Π΅Π½Π½ΡΠ΅ ΠΈΠ· ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ ΡΡΠ°ΡΡΠΊΠΎΠ², Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΡΡΡΡ Π²ΡΡΠΎΠΊΠΈΠΌ ΡΡΠΎΠ²Π½Π΅ΠΌ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Π°Π½ΡΠΈΠ³Π΅Π½ΠΎΠ² Π½Π°ΡΡΡΠ°Π»ΡΠ½ΡΡ ΠΊΠΈΠ»Π»Π΅ΡΠΎΠ² (CD57) ΠΈ ΠΌΠΎΠ»Π΅ΠΊΡΠ» Π°Π΄Π³Π΅Π·ΠΈΠΈ (CD58), Π° ΡΠ°ΠΊΠΆΠ΅ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΎΠ½Π½ΡΡ ΠΌΠΎΠ»Π΅ΠΊΡΠ» (CD38) ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΌΠΎΠ½ΠΎΠ½ΡΠΊΠ»Π΅Π°ΡΠ°ΠΌΠΈ ΠΊΡΠΎΠ²ΠΈ ΡΠ΅Ρ ΠΆΠ΅ Π±ΠΎΠ»ΡΠ½ΡΡ .5. ΠΠΎΠ½ΠΎΠ½ΡΠΊΠ»Π΅Π°ΡΠ½ΡΠ΅ Π»Π΅ΠΉΠΊΠΎΡΠΈΡΡ ΠΏΠ°ΡΠ°ΡΡΠΌΠΎΡΠ°Π»ΡΠ½ΡΡ ΡΡΠ°ΡΡΠΊΠΎΠ² ΠΏΠ΅ΡΠ΅Π½ΠΈ ΠΎΠ±Π»Π°Π΄Π°ΡΡ Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΠΎΠΉ ΠΠ-Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΡ ΠΈ ΡΠΈΡΠΎΡΠΎΠΊΡΠΈΡΠ½ΠΎΡΡΡΡ ΠΏΠΎ ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΡ ΠΊ Π°ΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ½ΡΠΌ ΠΊΠ»Π΅ΡΠΊΠ°ΠΌ, ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΌΠΎΠ½ΠΎΠ½ΡΠΊΠ»Π΅Π°ΡΠ½ΡΠΌΠΈ Π»Π΅ΠΉΠΊΠΎΡΠΈΡΠ°ΠΌΠΈ ΠΈΠ½ΡΠ°ΠΊΡΠ½ΡΡ ΡΡΠ°ΡΡΠΊΠΎΠ² ΠΏΠ΅ΡΠ΅Π½ΠΈ ΠΈ ΠΌΠΎΠ½ΠΎΠ½ΡΠΊΠ»Π΅Π°ΡΠ½ΡΠΌΠΈ ΠΊΠ»Π΅ΡΠΊΠ°ΠΌΠΈ ΠΏΠ΅ΡΠΈΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΡΠΎΠ²ΠΈ.6. ΠΡΠΈ ΠΈΠ½ΠΊΡΠ±Π°ΡΠΈΠΈ ΠΌΠΎΠ½ΠΎΠ½ΡΠΊΠ»Π΅Π°ΡΠ½ΡΡ Π»Π΅ΠΉΠΊΠΎΡΠΈΡΠΎΠ², Π²ΡΠ΄Π΅Π»Π΅Π½Π½ΡΡ ΠΈΠ· ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ ΡΡΠ°ΡΡΠΊΠΎΠ² ΠΏΠ΅ΡΠ΅Π½ΠΈ, Ρ ΠΠ-2, ΠΌΠΎΠ³ΡΡ Π±ΡΡΡ ΠΏΠΎΠ»ΡΡΠ΅Π½Ρ ΠΠΠ ΠΊΠ»Π΅ΡΠΊΠΈ, Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΡΡΠΈΠ΅ΡΡ Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΠΎΠΉ ΡΠΈΡΠΎΡΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΡ, ΡΠ΅ΠΌ ΠΠΠ, Π³Π΅Π½Π΅ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ ΠΈΠ· ΠΌΠΎΠ½ΠΎΠ½ΡΠΊΠ»Π΅ΡΠ½ΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΏΠ΅ΡΠΈΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΡΠΎΠ²ΠΈ.
Π‘ΠΏΠΈΡΠΎΠΊ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- ΠΠ°Π²ΡΠ΄ΠΎΠ² Π. Π., ΠΠΎΡΠΌΠ°Π½ΡΠΎΠ²ΠΈΡ Π. Π., ΠΠΈΡΠ΅Π»Π΅Π²ΡΠΊΠΈΠΉ Π. Π., ΠΠΎΠ»ΠΊΠΎΠ² Π. ΠΈ Π΄Ρ. ΠΠ΄ΠΎΠΏΡΠΈΠ²Π½Π°Ρ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ ΠΏΡΠΈ ΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΡΡ ΠΏΠ»Π΅Π²ΡΠΈΡΠ°Ρ : ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π ΠΎΡΡΠΈΠΉΡΠΊΠΈΠΉ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ 14—17.
- ΠΠΎΠ²ΠΈΠΊΠΎΠ² Π. Π. ΠΈ Π΄Ρ. ΠΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ ΠΏΡΠΈ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡΡ Π. Π. ΠΠΎΠ²ΠΈΠΊΠΎΠ², Π. Π. ΠΠ°ΡΠ°Π½Π΄Π°ΡΠΎΠ², Π*. Π. Π‘ΠΈΠ΄ΠΎΡΠΎΠ²ΠΈΡ. Π.: ΠΠ΅Π΄ΠΈΡΠΈΠ½Π°, 2002.
- ΠΠΊΡΠ»ΠΎΠ² Π. Π., ΠΡΠΎΠΌΠΎΠ² Π., ΠΠΎΠΉΡΠ΅Π½ΠΊΠΎΠ² Π. Π. ΠΠΎΠ΄ΡΠ»ΡΡΠΈΠΈ ΡΡΠ½ΠΊΡΠΈΠΈ ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΎΠ² ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΡΠΌΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°ΠΌΠΈ ΠΈ-ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΎΡΠ°ΠΌΠΈ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ1 ΠΎΡΠ²Π΅ΡΠ° ΠΠΊΡΡΠ°Π»ΡΠ½ΡΠ΅ Π²ΠΎΠΏΡΠΎΡΡ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΎΠΏΡΡ ΠΎΠ»Π΅ΠΉ: Π’Π΅Π·. Π΄ΠΎΠΊΠ». ΠΡΠ΅ΡΠΎΡΠ·. ΠΆΡΡΠ½Π°Π». 2000. 6 ΡΠΈΠΌΠΏΠΎΠ·ΠΈΡΠΌΠ°. Π ΠΈΠ³Π°, 1988. Π’. 2. 42—43.
- ΠΠ°ΡΠ΅Π½ΠΊΠΎΠ² Π. Π., ΠΠΈΠ½Π΅Π³ΠΈΠ½ Π. Π. ΠΡΠ½ΠΎΠ²Π½ΡΠ΅ ΡΠ²ΠΎΠΉΡΡΠ²Π° Π΄Π΅Π½Π΄ΡΠΈΡΠ½ΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡ. 2001. 22. 7—16.
- Π―ΡΡΠ³ΠΈΠ½ Π. Π. ΠΡΠ½ΠΎΠ²Ρ ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΠΈ. ΠΠΎΡΠΊΠ²Π°: ΠΠ΅Π΄ΠΈΡΠΈΠ½Π°, 1999. 216 Ρ.
- Akbari Π. et al. Essential role of NKT cells producing DL-4 and IL-13 in the development of allergen-induced airway hyperreactivity Nature Medicine. 2003. Vol. 9. P 582—588. 8. Ali Tahir S. M. et al. Loss of IFN-gamma production by invariant NK T cells in advanced cancer The Journal of Immunology. 2001. Vol. 167. P. 4046— 4050.
- Andrews D. M., Andoniou C. K, Scalzo A. A., van Dommelen S. L., Wallace M. E., Smyth M. J., Degli-Esposti M. A. Cross-talk between dendritic cells and* natural killer cells in viral infection Molecular immunology. 2005. Vol. 42. 4 P 547—555.
- Apostolou I. et al. Murine natural killer T (NKT) cells contribute to the granulomatous reaction caused by mycobacterial cell walls Proceedings of the
- Ardavin C Martinez del Hoyo G., Martin P., Anjuere F., Arias C. F., Marin A. R., Ruiz S., Parrillas V., Hernandez H. Origin and differentiation of dendritic cells Trends in immunology. 2001. Vol. 22. 12. P. 691−700.
- Arrunategui-Correa V., Lenz L., Kim H. S. CD Id-independent regulation of NKT cell migration and cytokine production upon Listeria monocytogenes infection Cellular immunology. 2004. Vol. 232. 1—2. P. 3 8 8
- Baxter A. G., Kinder S. J., Hammond K. J., Scollay R., and Godfrey D. I. Association between alphabetaTCR+CD4-CD8- T-cell deficiency and IDDM in NOD/Lt mice Diabetes. 1997. Vol. 146. P. 572—582.
- Beaudoin L., Laloux V., Novak J., Lucas B. and Lehuen A. NKT cells inhibit the onset of diabetes by impairing the development of pathogenic T cells specific for pancreatic beta cells Immunity. 2002. Vol. 7. P. 725—736.
- Benlagha K., Weiss A., Beavis A., Teyton L., and Bendelac A. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD Id tetramers The Journal of Experimental Medicine. 2000. Vol. 191. 11. P. 18 951 904.
- Bernsen M. R., Van der Velden A. W., Everse L. A., Dullens H. F. et al. Interleukin-2: hope in cases of cisplatin-resistant tumours Cancer immunol. Immunother. 1998. Vol. 46. P. 41—47.
- Berzins S. P. et al. Systemic NKT cell deficiency in NOD mice is not detected in peripheral blood: implications for human studies Immunology and Cell Biology. 2004. Vol. 82. P 247—252.
- Boon Π’., van der Bruggen P. Human tumor antigens recognized by T lymphocytes J Exp Med. 1996. Vol. 183. P. 725—729.
- Brigl M., Bry L., Kent S. C Gumperz J. E. and Brenner M. B. Mechanism of CD Id-restricted natural killer T cell activation during microbial infection Nature Immunology. 2003. Vol. 4. P. 1230—1237.
- Brossay L. et al. GDId-mediated Recognition- of an a-Galactosylceramide by Natural Killer T. Cells Is Highly Gonserved through Mammalian Evolution// Journal of Experimental Medicine: 1998. —Vol. 188. 8. P- 1521—1528.
- Brummer E., Stevens D. A. Mechanisms in opposite modulation of spleen cell and lymph node cell responses to mitogens following muramil dipeptide treatment in vitro II Cell. Immunol: 1985. Vol. 91. 2. P. 505—514:
- Carnaud- G. et al:. Gutting edge: cross-talk between- cells of the innate immune system: NKT cells rapidly activate NK cells The Journal of Immunology.— 1999. Vol 163: № 9″ P: 4647−1650- 26: Chamoto K., Kosaka A., Tsuji Π’., Matsuzaki J, Sato Π’., TakeshimaT., Iwakabe: K.,.Togashi Y., KodaT., Nishimura T. The critical role of Thl/Tcl circuit for the generation of tumor-specific CTL during tumor eradication in vivo by Thl-cell therapy Cancer Sci. 2003: Vol. 94, P. 924—928. 21. Chan Π- T. et a l Deficiency in beta (2)-microglobulini but nofcGDI, accelerates spontaneous lupus skin disease while inhibiting nephritis in MRE-Fas (lpr) nice: an1 example of disease regulation at the organ level The Journal of Immunology. 2001. Vol 167.— P. 2985—2990- 28: Ghiba: A. et al Suppression of collagen-induced arthritis by natural killer T cell activation with OCH a sphingosine-truncated analog of alpha-galactosylceramide Arthritis Rheumatism. 2004. Vol. 5 0 P: 305—313.
- Clemente G, Mihm M. C Bufalino R., Zurrida S., Collini P., Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma Cancer. 1996. Vol. 77. P. 1303—1310.
- Colonna M., Trinchieri G., Liu Y. J. Plasmacytoid dendritic cells in immunity Nature immunology. 2004. Vol. 5. 12. P. 1219—26.
- Cretney E., Takeda K., Yagita EL, Glaccum M., Peschon J. J., Smyth M.J. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosisinducing ligand-deficient mice J Immunol. 2002. Vol. 168.— P. 1356— 1361.
- Crowe N. Y. et al. Glycolipid Antigen Drives Rapid Expansion and Sustained Cytokine Production by NK T Cells The Journal of Immunology. 2003. Vol. 171. P 4020—4027.
- Crowe N. Y., Smyth M. J. and Godfrey D. I. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas The Journal of Experimental Medicine. 2002. Vol. 196. 1. P. 119—127. 34. Cui J. et al. Requirement for Valphal4 NKT cells in IL-12-mediated rejection of tumors Science. 1997. Vol. 278. 5343. P. 1623—1626.
- Dellabona P., Padovan E., Casorati M., Brockhaus M. and Lanzavecchia A. An invariant Voc24-JaQ/V[311 T cell receptor is expressed in all individuals by clonally expanded CD48 T cells Journal of Experimental Medicine. 1994. Vol. 180. P. 1171—1176.
- Dhodapkar M. V. et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma The Journal of Experimental Medicine. 2003. Vol. 197. 12. P. 1667— 1676.
- Dunn G.P., Brace Π. Π’., Ikeda H., Old L. J., Schreiber R. D. Cancer immunoediting: from immunosurveillance to tumor escape Nat Immunol. 2002. Vol.3. P 991—998.
- Dunn G. P., Old L. J., Schreiber R. D. The three es of cancer immunoediting Annu Rev Immunol. 2004. Vol. 22. P. 329—360.
- Eberl G. et al. Tissue-Specific Segregation of CD Id-Dependent and CDldIndependent NK T Cells The Journal of Immunology. 1999. Vol. 162. P. 6410—6419.
- Emoto M., Kaufmann S. H. Liver NKT cells: an account of heterogeneity Trends Immunology. 2003. Vol. 24. 7. P. 364—369.
- Engel A. M., Svane I. Ml, Rygaard J., Werdelin O. MCA sarcomas induced in scid mice are more immunogenic than MCA sarcomas induced in congenic, immunocompetent mice Scand J Immunol. 1997. Vol.45. P. 463—470.
- Enzler Π’., Gillessen S., Manis J. P., Ferguson Di, Fleming J., Alt F. W., Mihm M., Dranoff G. Deficiencies" of GM-CSF and interferon Ρ link inflammation and cancer//J Exp Med. 2003. Vol. 1 9 7 P 1213—1219.
- Exley M. A. et al. Cutting edge: compartmentalization of Π’Π«-like noninvariant CDld-reactive T cells in hepatitis Π‘ virus-infected Immunology. —2002. —Vol. 168. P 1519—1523.
- Faradji A., Bohbot A., Frost H., Schmitt-Goguel M., Siffert J. C DufoimP., Eber M., ballot C Wiesel ML L., Bergerat J. P. et al. Phase I study of liposomal MTP-PEactivated autologous monocytes administered intraperitoneally to patients with peritoneal carcinomatosis Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1991. Vol. 9. 7. P. 1251— 1260.
- Fischer K. et al. Mycobacterial phosphatidylinositol mannoside is a natural liver The Journal of antigen for CD Id-restricted T cells Proceedings of the National Academy of Sciences of the United States of America. 2004. Vol: 10 685—10 690.
- Fuji N., Ueda Y., Fujiwara H. et al. Antitumor effect of a-galactosylceramide (KRN7000) on spontaneous hepatic metastases requires endogenous interleukin 12 in the liver Clinical Cancer Research. 2000. Vol. 6. 8. P. 3380—3387. 101. 29. P.
- Fujii S. Application of natural killer T-cells to posttransplantation immunotherapy //Int J Hematol. 2005. Vol. 81. P. 1—5.
- Fujii S., Shimizu K., Kronenberg M- and Steinman R. M: Prolonged IFN-gammaproducing NKT response induced with alpha-galactosylceramide-loaded Nature Immunology. 2002. Vol. 3. P. 867—874.
- Giaccone G. et al- A phase: — F study of the natural killer T-cell ligand- alphaGalactosylceramide (KRN7000)* in patients with solid tumors Clinical Cancer Research.—2002. Vol- 8- PI 3702—3709!
- Godfrey D. I., Hammond K. J, Poulton L. D- et al- NKT cells: facts, functionsand fallacies Immunology Today. 2000: 21. P. 573—583.
- Godfrey D.I., Pellicci D- G., Smyth M. J. Immunology. The elusive NKT cell antigen is the search over? Science. 2004. Vol. 306. P. 1687−1689.
- Godfrey D. I MacDonald H. R., Kronenberg M., Smyth M- J- and Van Kaer L. NKT cells: whats in a name? Nature Reviews Immunology. 2004. Vol- 4. 3 P. 231—237.
- Gombert J.M. etal. Early quantitative and functional deficiency ofNKl±like thymocytes in the NOD mouse//European ournal of immunology. 1996- Vol- 2 6 1 2 P- 2989—2998.
- Gonzalez-Asegumolaza G., VamKaer L., Bergmann G.C., Wilson J- M, Schmieg J., Kronenberg M-, Nakayama Π’., Taniguchi Mi, Koezuka Y., Tsuji M NaturaEkiller DCs
- Groux H., OGarra A., Bigler M., Rouleau M., Antonenko S., de Vries J. E., Roncarolo M. G. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis //Nature. 1997. Vol. 389. P 737—742.
- Grubor-Bauk Π., Simmons A., Mayrhofer G. and Speck P. G. Impairedclearance of herpes simplex virus type 1 from mice lacking CDld or NKT cells expressing the semivariant Val4-Ja281 TCR The Journal of Immunology. 2003. Vol. 170. P. 1430—1434.
- Gumperz J. E.5 Miyake S., Yamamura T. and Brenner M. B. Functionally distinct subsets of CD Id-restricted natural killer T cells revealed by CDld tetramer staining The Journal of Experimental Medicine. 2002. Vol. 195. 5. P. 625— 636.
- Hammond K. J. et al. CD Id-restricted NKT cells: an interstrain comparison The Journal of Immunology. 2001. Vol. 167. P. 1164—1173.
- Hammond K. J. and Godfrey D. I. NKT cells: potential targets for autoimmune disease therapy? Tissue Antigens. 2002. Vol. 59. P: 353—363.
- Hammond K. J. and Kronenberg Mi Natural killer T cells: natural or. unnatural regulators of autoimmunity? Current Opinion in Immunology. 2003. Vol. 15. P. 683—689.
- Hammond K. J. et aL Alpha/beta-T cell receptor (TCR)+ CD4-CD8- (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD/Lt) mice by the influence of interleukin (IL)-4 and/or IL-10 The Journal of Experimental Medicine. 1998. Vol. 187. 7. P. 1047—1056.
- Hammond K. J. et all NKT cells are phenotypically and functionally diverse European Journal of Immunology. 1999. Vol. 29. P. 3768—3781.
- Hansen D. S., Siomos M. A., Buckingham L., Scalzo A. A. and Schofield L. Regulation of murine cerebral malaria pathogenesis by CD Id-restricted NKT cells
- Hayakawa- Y. et al. Critical contribution of IFN-gamma and NK cells, but not perforin- mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide European journal of immunology. 2001. Vol. 31. 6. P. 1720—1727.
- Hayakawa Y., Godfrey D. I. and Smyth M. J. Alpha-galactosylceramide: potential immunomodulatory activity and future application Current Medicinal Chemistry. 2004. Vol. 11. 2. P. 241—252.
- Hayakawa Y., Rovero S., Forni* G. and Smyth M. J. Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependenf carcinogenesis Proceedings of the National Academy of Sciences of the United States of America. 2003. Vol. 100. 16. P. 9464—9469.
- Hayes R. L., Arbit E., Odaimi M., Pannullo S., Scheff R., Kravchinskiy D., Zaroulis C. Adoptive cellular immunotherapy for the treatment of malignant gliomas Crit Rev Oncol Hematol. 2001. Vol. 39. P. 31—42.
- Heath W., Belz G., Behrens G., Smith C Forehan S., Parish I., Davey G., Wilson N., Carbone F., Villadangos J. Gross-presentation, dendritic cell subsets, and the generationof immunity to cellular antigens Immunological reviews. 2004. 199. P 9—26.
- Herberman R. B. Possible role of natural killer cell and other effector cells in immune surveillance against cancer J. Investigative Dermatology. 1984. Vol. 83. 1 P 137—140.
- Hermon C Beral V. Breast cancer mortality rates are levelling off or beginning to decline in many western countries: analysis of time trends, age-cohort and ageperiod models of breast cancer mortality in 20 countries Br J Cancer. 1996. Vol. 73. 7. P. 955—960.
- Hong S. et al. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice Nature Medicine. 200 V. Vol.7. P 1052—1056.
- Hong S.M. et al. Lipid antigen presentation in the immune system- lessons learned from CD Id knockout mice Immunological Reviews. 1999. Vol. 169. 1 P. 31—44.
- Hong S., Van Kaer L. Immune privilege: keeping an eye on natural killer T cells J Exp Med. 1999. Vol. 190. 9. P. 1197−1200. 76: Hori Π’., 1Π‘ Mise, N. Kan, T. Okino, K. Satoh, S. Yamasaki et al. Therapeutic and life-prolonging effect of intrapleural injection with a streptococcal preparation, OK432, and IL2-cultured effusion lymphocytes to breast cancer patients with malignant pleural effusion Biotherapy. 1992. Vol. 5. 1. P. 21—29.
- Ichinose Y., Yano Π’., Asoh H., Yokoyama H., Fukuyama Y., Miyagi J., Kuninaka S., Terazaki Y. Intraoperative intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis J Surg Oncol. 1997. Vol. 66. 3. P. 196— 200.
- Ikeda H., Old L. J., Schreiber R. D. The roles of EFN Ρ in protection against tumor development and cancer immunoediting Cytokine Growth Factor Rev. 2002. Vol. 1 3 P 95—109.
- Ishihara S. et al. CD8+NKR-PrA+ T cells preferentially accumulate in human liver European Journal of Immunology. 1999. Vol. 29. P. 2406—2413. 80: Jahng A. W. et al. Activation of natural killer T cells potentiates or, prevents experimental autoimmune encephalomyelitis The Journal of Experimental Medicine. 2001. Vol. 194. 12. P. 1789—1799.
- Johnson T. R, Hong S. M., Van Kaer L., Koezuka Y. and Graham B. S. NK T cells contribute to expansion of CD8(+) T cells and amplification of antiviral immune responses to respiratory syncytial virus Journal of Virology. 2002. Vol. 76. 9. P. 4294—4303.
- Jones P. D., Castro J. E. Immunological mechanisms in metastatic spread and the antimetastatic effects of C. parvum. British journal of cancer. 1977. Vol. 35. 5 P 519—527.
- Kaplan D. H., Shankaran V., Dighe A. S., Stockert E., Aguet M., Old L. J., Schreiber R. D. Demonstration of an interferon y-dependent tumor surveillance system in immunocompetent mice Proc Natl Acad Sci USA. 1998. Vol. 95. P. 7556—7561.
- Kasper H. U., Drebber U., Zur Hausen A. et al. Dominance of CD4+ alpha/beta T-cells and inferior role of innate immune reaction in the liver metastases Anticancer Research. 2003. Vol. 23. 4. P. 3175—3181.
- Kaufmann S. H. New issues in tuberculosis Annals of the rheumatic diseases. 2004. Vol. 63. P. 50—56.
- Kawakami K., Kinjo Y., Uezu K., Yara S., Miyagi K., Koguchi Y Nakayama Π’., Taniguchi M., Saito A. Monocyte chemoattractant protein-1-dependent increase of V alpha 14 NKT cells in lungs and their roles in Thl response and host defense in cryptococcal infection. Journal of immunology (Baltimore, Md. 1950). 2001. Vol. 167. Π P 6525—6532.
- Kawano Π’., Cui J., Koezuka Y., Toura I., Kaneko Y., Motoki K., Ueno H., Nakagawa R., Sato H., Kondo E., Koseki H., Taniguchi M. CD Id-restricted and TCR-mediated activation of valphal4 NKT cells by glycosylceramides Science (New York, N.Y.). 1997. Vol. 278. 5343. P. 1626—1629.
- Kawano T. et al. Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells Cancer Research. 1999. Vol. 59. P. 5102—5105.
- Kawano Π’. et al. CD Id-restricted and TCR-mediated activation of Val4 NKT cells by glycosylceramides Science. 1997. Vol. 278. 5343. P. 1626—1629.
- Kemp R. A., Backstrom Π. Π’., Ronchese F. The phenotype of type 1 and type 2 CD8+ T cells activated in vitro is affected by culture conditions and correlates with effector activity Immunology. 2005. Vol. 115. 3. P. 315—324.
- Kenna Π’., Mason L. G., Porcelli S. A. et al. NKT cells from normal and tumorbearing human liver are phenotypically and functionally distinct from murine NKT cells Journal of Immunology. 2003. Vol. 166. 11. P. 6578—6584.
- Kenna T. et al. NKT Cells from Normal and Tumor-Bearing Human Livers Are Phenotypically and Functionally Distinct from Murine NKT Cells The Journal of Immunology. 2003. Vol. 171. P. 1775—1779.
- Kikuchi A. et al: In vitro anti-tumour activity of alpha-galactosylceramide- stimulated human invariant Valpha24+NKT cells against melanoma British Journal of Cancer. 2001. Vol. 85. P. 741—746.
- Kita H. et al. Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CDld tetramer Gastroenterology. 2002. Vol. 123. P 1031—1043.
- Kitamura H., Iwakabe K., Yahata Π’., Nishimura S., Ohta A., Ohmi Y., Sato M., Takeda K., Okumura K., Van Kaer L., Kawano Π’., Taniguchi M., Nishimura T. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells The Journal of experimental medicine. 1999. Vol. 189. 7. P. 1121—1128.
- Kosaka A., Wakita D., Matsubara N., Togashi Y., Nishimura S., Kitamura H., Nishimura T. AsialoGMl+CD8+ central memory-type T cells in unimmunized mice as novel immunomodulator of IFN-gamma-dependent type 1 immunity Int Immunol. 2007. Vol. 19. 3. 249—256.
- Korsgren M. et al. Natural killer cells determine development of allergen-induced eosinophilic airway inflammation in mice The Journal of Experimental Medicine. 1999. —Vol. 189. P. 553—562.
- Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes Annual review of immunology. 2005. Vol. 23. P. 877—900.
- Kronenberg M. and Gapin L. The unconventional lifestyle of NKT cells Nature Reviews Immunology. 2002. Vol. 2. 8. P. 557—568.
- Krutzik S. R, Tan Π., Li H., Ochoa M. Π’., Liu P. Π’., Sharfstein S. E., Graeber T. G., Sieling P. A., Liu Y. J., Rea T. H., Bloom B. R., Modlin R. L. TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells Nature medicine. 2005. Vol. 11. 6. P. 653—660. 103. Lee P. Π’., Benlagha K., Teyton L. and Bendelac A. Distinct functional lineages of human V alpha-24 natural killer T cells The Journal of Experimental Medicine. 2002. —Vol. 195. 5. P 637—641.
- Lehuen A. et al. Overexpression of natural killer T cells protects Val4-Ja281 transgenic nonobese diabetic mice against diabetes The Journal of Experimental Medicine. 1998. —Vol. 188. P 1831—1839.
- Levy O. et al. Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells The Journal of Infectious Diseases. 2003. Vol. 188. P. 948—953.
- Lisbonne M. et al. Cutting edge: invariant ValphaH NKT cells are required for allergen-induced airway inflammation and hyperreactivity in an experimental asthma model The Journal of Immunology. 2003. Vol. 171. P. 1637—1641. 107. Liu X., Li D., Zhang C Ba D. et al. Treatment of 121 patients with malignant effusion due to* advanced lung cancer by intrapleural transfer of autologus or allogenic LAK cells combined witbRIL-2 Med. Sc J. 1993. Vol. 8. P. 186—189.
- Lucas M., Gadola S., Meier U. et al. Frequency and phenotype of Circulating Va24/Vbll double-positive natural killer Y cells during hepatitis Π‘ infection Journal of Virology. 2003. Vol. 77. 3. P. 2251—2257.
- Matsuda J. L. et al. Mouse VI4i natural killer T cells are resistant to cytokine polarization in vivo Proceedings of the National Academy of Sciences of the United States of America. 2003. Vol. 100. 14. P. 8395—8400.
- Matsuda J. L. et al. Tracking the Response of Natural Killer T Cells to a Glycolipid Antigen Using CD Id Tetramers The Journal of Experimental Medicine. 2000i Vol. 192. 5. P. 741—754.
- Mempel M. et al. Natural killer T cells restricted by the monomorphic MHC class lb CDldl molecules behave like inflammatory cells The Journal of Immunology. 2002. Vol. 168. P. 365—371.
- Metelitsa!X. S. et al: Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CDld. with bound ligand or indirectly by producing IL-2 to activate NK cells The Journal of Immunology. 2001. Vol. 167. P. 3114— 3122.
- Miyamoto K., Miyake S. and Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells Nature. 2001. Vol. 413. P. 531—534.
- Mosmann T. R., Sad S. The expanding universe of T-cell subsets: Thl, Th2 and more. Immunol Today. 1996. Vol. 17. P. 138—146.
- Motohashi S. et al. Preserved IFN-alpha production of circulating V alpha 24 NKT cells in primary lung cancer patients International Journal of Cancer. 2002. Vol. 1 0 2 2 P 159—165.
- Mule J. J., Shu S., Schwarz S.I. Adoptive immunotherapy of established pulmonary metastases witrrLAK cells and recombinant interleukin-2 Science. 1984. —Vol. 225. 4 6 6 9 P 1487—1489.
- Nakagawa R., Nagafune I., Tazunoki Y. et al. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by a-galactosylceramide in
- Naumov Y.N. et al. Activation of CD Id-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets Proceedings of the National Academy of Sciences of the United States of America. 2001. Vol. 98. 24: P. 13 838—13 843.
- Nieda M. et al. Therapeutic activation of V{alpha}24+V{beta}ll+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity Blood. 2004. Vol. 103. 2. P. 383—389.
- Nieuwenhuis E. E., Neurath M. F., CorazzaN., Iijima H., Trgovcich J., Wirtz S., Glickman J., Bailey D., Yoshida M., Galle P. R., Kronenberg M., Birkenbach M., Blumberg R. S. Disruption of T helper 2-immune responses in Epstein-Barr virusinduced gene 3-deficient mice Proceedings of the NationalAcademy of Sciences of the United States of America. 2002. Vol. 99. 26. P. 16 951—16 956.
- Nishikawa H. et al. CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses Proceedings of the National Academy of Sciences of the United States of America. 2003. Vol. 100. 19. P 10 902—10 906.
- Norris S., Doherty D. G., Collins C. et al. Natural T cells in the human liver: cytotoxic lymphocytes with dual T cell and natural killer cell phenotype and function are phenotypically heterogeous and include Va24-JaQ and gdT cell receptor bearing cells Human Immunology. 1999. Vol. 60. P. 20—31.
- Ohteki Π’., Fukao Π’., Suzue K., Maki C Ito M., Nakamura M., Koyasu. S. Interleukin 12-dependent interferon Ρ production by CD8a+ lymphoid dendritic cells //JExpMed. 1999. Vol. 189. P 1981—1986. 124. Old L. J., Chen Y. T. New paths in human cancer serology J Exp Med. 1998.—Vol. 187. P 1163—1167.
- Ortaldo J. R. et al. Dissociation of NKT Stimulation, Cytokine Induction, and NK Activation In Vivo by the Use of Distinct TCR-Binding Ceramides The Journal of Immunology. 2004. Vol. 172. P 943—953.
- Ostrand-Rosenberg S. et al. Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent The Journal of Immunology. 2002. Vol. 169. P. 5796—5804. 127. Pal E. et al. Costimulation-Dependent Modulation of Experimental Autoimmune Encephalomyelitis by Ligand Stimulation of V14 NK T Cells The Journal of Immunology. 2 0 0 1 Vol. 166: P 662—668.
- Park S. H, Kyin Π’., Bendelas A., Carnaud G. The contribution of NKT cells, NK cells, and other gamma-chain-dependent non-T non-B cells to EL-12-mediated rejection of tumors The Journal of Immunology. 2003. Vol. 170. 3. P. 1197—1201.
- Park S. H., Yang S. H., Lee Π‘ G., Youn J. W., Chang J., Sung Y. Π‘ Efficient induction of T helper 1 CD4+ T-cell responses to hepatitis Π‘ virus core and E2 by a DNA prime-adenovirus boost Vaccine. 2003. Vol. 21. P. 4555—4564.
- Pejawar S. S., Parks G. D., Alexander-Miller M. Abortive versus productive viral infection of dendritic cells with a paramyxovirus results in differential upregulation of select costimulatory molecules Journal of virology. 2005. Vol. 79. 12. P. 7544—7557.
- Perm I. Malignant melanoma in organ allograft recipients Transplantation. 1996. Vol. 61. P. 274—278.
- Porcelli S., Yockey C. E., Brenner M.B. and Balk S. P. Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4−8- alpha/beta T cells demonstrates preferential use of several Vbeta genes- and an invariant TCR alpha chain. Journal of Experimental Medicine. 1993. Vol. 178. P. 1—16.
- Poulton L. D. et al. Cytometric and functionalanalyses of NK and NKT cell deficiencies in NOD mice International Immunology. 2001. Vol. 13. β*7. P. 887—896.
- Prell et al. Frequency of Valpha24+CD161+ natural killer T cells and invariant TCRAV24-AJ18 transcripts in atopic and non-atopic individuals Immunobiology. 2003. Vol. 208. 4. P. 367—380.
- Prussin C. and Foster B. TCR V-alpha-24 and V-beta-11 coexpression defines a human NKl T cell analog containing a unique ThO subpopulation The Journal of Immunology. 1997. Vol. 159. P. 5862—5870.
- Pulendran Π., Banchereau J., Maraskovsky E., Maliszewski C. Modulating the immune response with dendritic cells and their growth factors Trends in immunology. 2001. Vol. 22. 1. p. 41—47.
- Roberts T. J., UnY., Spence P. M., Van Kaer L. and Brutkiewicz R. R. CDldl- dependent control of the magnitude of an acute antiviral immune response The Journal of Immunology. 2004. Vol. 172. P. 3454—3461.
- Rosenberg S. A., Lotze B:5 Muul L. et al. Observation in the systemic administration of autologous lymphokineactivate killer cells and recombinant interleukin-2 to patients with metastatic cancer N. Engl. J. Med. 1985. Vol. 314. P 1485—1492.
- Rosenberg S. A., Lotze Π., Yang J. C. et al. Prospective randomized trial of high dose of IL-2 alone and in conjugation with LAK for treatment of patients with advanced cancer J. Natl. Cancer Inst. 1993. Vol. 85. P. 662—632.
- Rosenberg S. A. A new era for cancer immunotherapy based on the genes that encode cancer antigens Immunity. 1999. Vol. 10. P. 281—287.
- Sakaguchi S., Sakaguchi N., Shimizu J., Yamazaki S., Sakihama T.,"Itoh M., Kuniyasu Y., Nomura Π’., Toda M., Takahashi T. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance Immunol Rev. 2001. Vol. 182. P. 18—32.
- Sato K., Yamashita N., Yamashita N., Baba M., Matsuyama T. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse Immunity. 2003. Vol. 18. P. 367—379.
- Sato M., Chamoto Π., Tsuji Π’., Iwakura Y., Togashi Y., Nishimura T. Thl cytokine- conditioned bone marrow-derived dendritic cells can bypass the requirement for Th functions during the generation of CD8+ CTL. J Immunol. 2001. —Vol. 167. P 3687—3691.
- Schmieg J., Yang G., Franck R. W. and Tsuji M. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide The Journal of Experimental Medicine. 2003. —Vol. 198. 11. P 1631—1641.
- Schmieg J., Yang G., Franck R. W., Van Rooijen N., Tsuji M. Glycolipid presentation to natural killer T cells differs in an organ-dependent fashion Proc Natl Acad Sci USA. 2005. Vol. 102. 4 P. 1127−1132.
- Shankaran V., Ikeda Hi, Brace Π. Π’., White J. M., Swanson P. E., Old L. J., Schreiber R. D. IFNy and lymphocytes prevent primary tumour" development and shape tumour, immunogenicity Nature. 2001. Vol. 410. P. 1107—1 111.
- Sharif S. et al. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes Nature Medicine. 2001. Vol. 7. P. 1057—1062.
- Shiiba K., Suzuki R., Kawakami K. et al. Interleukin-2-activated killer cells: generation in collaboration with interferon and with supressor in cancer patients Cancer Immunol. Immunother. 1986. Vol. 21. P. 119—128.
- Sidobre S. et al. The V14 NKT Cell TCR Exhibits High-AfFmity Binding to a Glycolipid/CDld Complex The Journal of Immunology. 2002. Vol. 169. P. 1340—1348.
- Singh A. K., Yang J. Q.," Parekh V. V., Wei J., Wang Π‘ R., Joyce S., Singh R. R., Van Kaer L. The natural killer T cell ligand alpha-galactosylceramide prevents or promotes pristane-induced lupus in mice. European journal of immunology. 2005.—Vol.35. 4 P 1143—1154.
- Singh Π. Π. et al. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis The Journal of Experimental Medicine. 2 0 0 1 —Vol. 194. 12. P 1801—1811.
- Smiley S. Π’., Lanthier P. A., Couper K. N., Szaba F. M., Boyson J. E., Chen W., Johnson L. L. Exacerbated susceptibility to infection-stimulated immunopathology in CD Id-deficient mice Journal of immunology (Baltimore, Md. 1950). 2005. Vol. 174. 12. P 7904—7911.
- Smyth M. J., Thi K. Y., Street S. E., MacGregor D., Godfrey D. J, Trapani J. A. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma J Exp Med. 2000. Vol. 192. P. 755—760.
- Smyth. M. J., Thia K. Y., Street S. E., Cretney E., Trapani J. A., Taniguchi M., Kawano Π’., Pelikan S. Π., Crowe N. Y., Godfrey D. I. Differential tumor surveillance by natural killer (NK) and NKT cells J Exp Med. 2000. Vol 191. P. 661—668.
- Smyth M. J. et a l Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer The Journal of Experimental Medicine. 2005-—Vol.201.—№ 12. P 1973—1985.
- Smyth M. J. and Godfrey D. Π. NKT cells and tumor immunity a doubleedged sword Nature Immunology. 2000. 1. P. 459—460.
- Smyth M. J., Crowe N. Y., Takeda K., Yagita H. and Godfrey D. I. NKT cells conductors of tumor immunity? Current Opinion in Immunology. 2002. Vol 14. P 165—171.
- Soda H., Koda K., Yasutomi J., Oda K., Takiguchi N., Saito N., Nakajima N. Adoptive immunotherapy for, advanced cancer patients using in vitro activated cytotoxic T lymphocytes J Surg Oncol. 1999. Vol 72. 4. P. 2 1 1 217.
- Stanic A. K. et a l Another View of T Cell Antigen Recognition: Cooperative Engagement of Glycolipid Antigens by Val4Jal8 Natural TGR The Journal of Immunology. 2003. Vol 171. P. 4539—4551.
- Stetson D. Π. et al. Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid1 effector function The Journal of Experimental Medicine. 2003. Vol. 198. 7. P. 1069—1076.
- Stober D., Jomantaite I., Schirmbeck R., Peimann J. NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo The Journal of Immunology. 2003. Vol. 170. 5. P. 2540—2548.
- Street S. E., Cretney E., Smyth M.J. Perforin and interferon-y activities independently control tumor initiation, growth, and, metastasis Blood. 2201. Vol.97.—P. 192—197. 163. Su Z., Segura M., Morgan K., Loredo-Osti J. C Stevenson M. M. Impairment of protective immunity to blood-stage malaria by concurrent nematode infection Infection and immunity. 2005. Vol. 73. 6. P. 3531—3539.
- Svane I. M., Engel A. M., Nielsen M. Π., Ljunggren H. G., Rygaard J., Werdelin O. Chemically induced sarcomas from nude mice are more immunogenicthan similar sarcomas from congenic normal mice Eur Jf Immunol. 1996. Vol. 26. P. 1844—1850.
- Takeda A., Homma S., Okamoto Π’., Kufe D., Ohno T. Immature dendritic cell/tumor cell fusions induce potent antitumour immunity European journal of clinical investigation. 2003. Vol. 33. 10. P. 897—904.
- Takeda K., Kaisho Π’., Akira S. Toll-like receptors Annu Rev Immunol. 2003. —Vol. 21. P 335—376.
- Terabe M., Berzofsky J. A. NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis Trends Immunol. 2007. Vol. 28. 11. P. 491—496.
- Terabe M: et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway Nature immunology. 2000. Vol. 1. 6 P. 515—520.
- Thomas L. On immunosurveillance in human cancer Yale J Biol Med. 1982. —Vol. 55. P 329−333.
- Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity Nat Rev Immunol. 2003. Vol. 3. P. 133—146.
- Trobonjaca Z., Kroger A., Stober D. et al. Activating immunity in the liver. Π. IFN-P attenuates NK cell-dependent liver injury triggered by liver NKT cell activation// The Journal of Immunology. 2002. Vol. 168. 8. P. 3763—3770.
- Trobonjaca Z., Leithauser F., Moller P. et al. Activating immunity in the liver: L Liver dendritic cells (but not hepatocytes) are potent activators of IFN-a release by liver NKT cells The Journal of Immunology. 2001. Vol. 167. 3. P. 1413—1422. 173: Van der Vliet H. J. et al: Circulating V (alpha24+) Vbetall+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactivetissue damage Clinical Immunology. 2001. Vol. 100. P. 144—148.
- Varma T. K., Lin C. Y., Toliver-Kinsky Π’. E. et all Endotoxin-induced gamma interferon- production: contributing cell types and key regulatory factors Clinical and Diagnostic Laboratory Immunology. 2002. Vol: 9. 3. P. 530— 543.
- Wang Π., Geng Y B a n d Wang Π‘ R. CD 1-restricted NK T Cells Protect Nonobese Diabetic Mice from Developing Diabetes The Journal of Experimental Medicine. 2001. Vol. 194. 3. P. 313—320.
- West W. H., Tauer K. W., Yanneli J. R. et al. Constant infusion EL-2 in adoptive immunotherapy of advanced cancer N. Engl. J.Mad. 1987. Vol: 316. P 898—905.
- Wilson S. B. and Delovitch T. L. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. //Nature Reviews Immunology. 2003. 3 P. 211—222.
- Yang Y., Huang Π’., Huang X., Pardoll D. M: Persistent Toll-like receptor signals, are required for reversal of regulatory T cell-mediated CD8 tolerance Nat Immunol. 2004. Vol. 5. P. 508—515.
- Yang J. Q. et al. Repeated alpha-galactosylceramide administration results in expansion of NK T cells and alleviates inflammatory dermatitis in MRL-lpr/lpr mice The Journal of Immunology. 2003. Vol. 171. P. 4439—4446.
- Yang J. Q. et al. CD Id deficiency exacerbates inflammatory dermatitis in MRLlpr/lpr mice European Journal of Immunology. 2004. Vol. 34. P. 1723— 1732.
- Zeng D., Lee M. K., Tung J., Brendolan A. and Strober S. Cutting edge: a role for CDl in the pathogenesis of lupus in NZB/NZW mice The Journal of Immunology. 2002. Vol. 164. P. 5000—5004.
- Zeng D., Liu Y., Sidobre S., Kronenberg M. and Strober S. Activation of natural killer T cells in NZB/W mice induces Thl-type immune responses exacerbating lupus Journal of Clinical Investigation. 2003. Vol. 112. P. 1211—1222.